Arcus Biosciences Announces New Employment Inducement Grants
Arcus Biosciences (NYSE:RCUS), a clinical-stage global biopharmaceutical company focused on developing differentiated molecules and combination therapies for cancer, has announced new employment inducement grants. The Compensation Committee of the Company's Board of Directors has granted five new employees options to purchase 38,600 shares of the Company's common stock at an exercise price of $15.71 per share, which was the closing price on September 23, 2024. Additionally, restricted stock units to acquire 19,300 shares of the Company's common stock were granted. These equity awards were granted under the Company's 2020 Inducement Plan, approved by the Board of Directors in January 2020 pursuant to the "inducement exception" under NYSE Listed Company Manual Rule 303A.08.
Arcus Biosciences (NYSE:RCUS), un'azienda biopharmaceutica globale nelle fasi cliniche che si concentra sullo sviluppo di molecole differenziate e terapie combinate per il cancro, ha annunciato nuovi incentivi all'occupazione. Il Comitato per la Compensazione del Consiglio di Amministrazione dell'Azienda ha concesso opzioni per l'acquisto di 38.600 azioni a cinque nuovi dipendenti delle azioni ordinarie dell'Azienda a un prezzo di esercizio di $15,71 per azione, che era il prezzo di chiusura del 23 settembre 2024. Inoltre, sono state concesse unità azionarie riservate per acquisire 19.300 azioni delle azioni ordinarie dell'Azienda. Questi premi azionari sono stati concessi nell'ambito del Piano di Induzione 2020 dell'Azienda, approvato dal Consiglio di Amministrazione nel gennaio 2020 in conformità all'
Arcus Biosciences (NYSE:RCUS), una empresa biofarma global en etapa clínica que se centra en desarrollar moléculas diferenciadas y terapias combinadas para el cáncer, ha anunciado nuevas concesiones de incentivos para el empleo. El Comité de Compensación de la Junta Directiva de la Empresa ha otorgado a cinco nuevos empleados opciones para comprar 38,600 acciones de las acciones comunes de la Empresa a un precio de ejercicio de $15.71 por acción, que fue el precio de cierre el 23 de septiembre de 2024. Además, se otorgaron unidades de acciones restringidas para adquirir 19,300 acciones de las acciones comunes de la Empresa. Estos premios de capital se otorgaron bajo el Plan de Inducción 2020 de la Empresa, aprobado por la Junta Directiva en enero de 2020 de acuerdo con la
Arcus Biosciences (NYSE:RCUS)는 암을 위한 차별화된 분자 및 복합 요법 개발에 주력하는 임상 단계의 글로벌 생명공학 회사로, 새로운 고용 유인 보조금을 발표했습니다. 회사 이사회의 보상 위원회는 5명의 신규 직원에게 38,600주에 대한 매수 선택권을 부여했습니다, 행사 가격은 주당 $15.71으로 2024년 9월 23일의 종가였습니다. 또한, 19,300주의 주식을 취득하기 위한 제한된 주식 단위가 부여되었습니다. 이러한 자본 상은 2020년 유인 계획에 따라 부여되었으며, 이는 2020년 1월 이사회에서 승인되었으며 NYSE 상장 기업 매뉴얼 규칙 303A.08에 따른
Arcus Biosciences (NYSE:RCUS), une entreprise biopharmaceutique mondiale en phase clinique axée sur le développement de molécules différenciées et de thérapies combinées pour le cancer, a annoncé de nouvelles subventions d'incitation à l'emploi. Le Comité de Rémunération du Conseil d'administration de l'entreprise a accordé des options d'achat de 38 600 actions à cinq nouveaux employés des actions ordinaires de l'entreprise à un prix d'exercice de 15,71 USD par action, correspondant au prix de clôture du 23 septembre 2024. De plus, des unités d'actions restreintes pour acquérir 19 300 actions des actions ordinaires de l'entreprise ont été accordées. Ces attributions d'équité ont été accordées dans le cadre du Plan d'Incitation 2020 de l'entreprise, approuvé par le Conseil d'administration en janvier 2020 conformément à l'
Arcus Biosciences (NYSE:RCUS), ein klinisches globales Biopharma-Unternehmen, das sich auf die Entwicklung von differenzierten Molekülen und Kombinationstherapien für Krebs konzentriert, hat neue Anreize für die Beschäftigung angekündigt. Der Vergütungsausschuss des Vorstands des Unternehmens hat fünf neuen Mitarbeitern Optionen zum Kauf von 38.600 Aktien der Stammaktien des Unternehmens zu einem Ausübungspreis von 15,71 USD pro Aktie gewährt, was dem Schlusskurs am 23. September 2024 entspricht. Zusätzlich wurden auferlegte Aktieneinheiten für den Erwerb von 19.300 Aktien der Stammaktien des Unternehmens gewährt. Diese Eigenkapitalvergünstigungen wurden im Rahmen des 2020 Incentive-Plans des Unternehmens gewährt, der im Januar 2020 vom Vorstand genehmigt wurde und sich auf die
- Arcus Biosciences is attracting new talent with stock options and restricted stock units
- The company is expanding its workforce, potentially indicating growth or new projects
- None.
About Arcus Biosciences
Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination medicines for people with cancer. In partnership with industry collaborators, patients and physicians around the world, Arcus is expediting the development of first- or best-in-class medicines against well-characterized biological targets and pathways and studying novel, biology-driven combinations that have the potential to help people with cancer live longer. Founded in 2015, the company has expedited the development of multiple investigational medicines into clinical studies, including new combination approaches that target TIGIT, PD-1, the adenosine axis (CD73 and dual A2a/A2b receptor), HIF-2a, CD39, and AXL. For more information about Arcus Biosciences’ clinical and preclinical programs, please visit www.arcusbio.com.
Inducement PR
Source: Arcus Biosciences
View source version on businesswire.com: https://www.businesswire.com/news/home/20240924325020/en/
Investor Inquiries:
Pia Eaves
VP of Investor Relations & Strategy
(617) 459-2006
peaves@arcusbio.com
Media Inquiries:
Holli Kolkey
VP of Corporate Communications
(650) 922-1269
hkolkey@arcusbio.com
Source: Arcus Biosciences
FAQ
What stock options did Arcus Biosciences (RCUS) grant to new employees on September 23, 2024?
How many restricted stock units did Arcus Biosciences (RCUS) grant in its recent employment inducement awards?
Under which plan were the new employment inducement grants made by Arcus Biosciences (RCUS)?
What is the main focus of Arcus Biosciences (RCUS) as a company?
